Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer's Disease
Alzheimer's Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an u...
Saved in:
Main Authors: | Clive Ballard (Author), Gareth Williams (Author), Anne Corbett (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2013-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease
by: Soo Youn Lee, et al.
Published: (2020) -
Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
by: Yong Li, et al.
Published: (2020) -
The hungry stomach: physiology, disease and drug development opportunities
by: Gareth J Sanger, et al.
Published: (2011) -
Knowledge Mapping of Drug Repositioning’s Theme and Development
by: Lang X, et al.
Published: (2023) -
Clinical trials on drug repositioning for COVID-19 treatment
by: Sandro G. Viveiros Rosa, et al.
Published: (2020)